Search Results - "Bielack, S.S"

Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients by Longhi, A, Bielack, S.S, Grimer, R, Whelan, J, Windhager, R, Leithner, A, Gronchi, A, Biau, D, Jutte, P, Krieg, A.H, Klenke, F.M, Grignani, G, Donati, D.M, Capanna, R, Casanova, J, Gerrand, C, Bisogno, G, Hecker-Nolting, S, De Lisa, M, D'Ambrosio, L, Willegger, M, Scoccianti, G, Ferrari, S

“…Abstract Purpose Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective…”
Get full text

The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols by Andreou, D., Bielack, S.S., Carrle, D., Kevric, M., Kotz, R., Winkelmann, W., Jundt, G., Werner, M., Fehlberg, S., Kager, L., Kühne, T., Lang, S., Dominkus, M., Exner, G.U., Hardes, J., Hillmann, A., Ewerbeck, V., Heise, U., Reichardt, P., Tunn, P. -U.

“…Local recurrence (LR) in osteosarcoma is associated with very poor prognosis. We sought to evaluate which factors correlate with LR in patients who achieved…”
Get full text

State-of-the-art approach in selective curable tumors: bone sarcoma by Bielack, S. S., Carrle, D.

Get full text

Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs by Fuchs, N., Bielack, S. S., Epler, D., Biding, P., Delling, G., Körholz, D., Graf, N., Heise, U., Jürgens, H., Kotz, R., Salzer-Kuntschik, M., Weinel, P., Werner, M., Winkler, K.

“…Background: In an effort to intensify osteosarcoma therapy, systemic ifosfamide was added pre- and postoperatively to an already aggressive three-drug regimen…”
Get full text

Osteosarcoma by Ritter, J., Bielack, S. S.

“…The successful treatment of patients with osteosarcoma requires close cooperation within an experienced multidisciplinary team including pediatric or medical…”
Get full text

Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties? by Bielack, S.S., Erttmann, R., Kempf-Bielack, B., Winkler, K.

“…Anthracyclines are among the most active agents against both solid tumours and haematological malignancies. Doxorubicin is the most widely used agent of this…”
Get full text

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment by Whelan, J.S., Bielack, S.S., Marina, N., Smeland, S., Jovic, G., Hook, J.M., Krailo, M., Anninga, J., Butterfass-Bahloul, T., Böhling, T., Calaminus, G., Capra, M., Deffenbaugh, C., Dhooge, C., Eriksson, M., Flanagan, A.M., Gelderblom, H., Goorin, A., Gorlick, R., Gosheger, G., Grimer, R.J., Hall, K.S., Helmke, K., Hogendoorn, P.C.W., Jundt, G., Kager, L., Kuehne, T., Lau, C.C., Letson, G.D., Meyer, J., Meyers, P.A., Morris, C., Mottl, H., Nadel, H., Nagarajan, R., Randall, R.L., Schomberg, P., Schwarz, R., Teot, L.A., Sydes, M.R., Bernstein, M., Pickering, James, Joffe, Nicola, Kevric, Matthias, Sorg, Benjamin, Villaluna, Doojduen, Wang, Caroline, Perisoglou, Martha, Trani, Leonardo, Potratz, Jenny, Carrle, Dorothe, Wilhelm, Miriam, Zils, Katja, Teske, Carmen

“…This manuscript describes the experience from registration until randomisation for a cohort of 2260 patients with osteosarcoma who joined the EURAMOS-1 trial…”
Get full text

EURO-B.O.S.S.: Outcome in rare non-osteosarcoma bone sarcoma by Reichardt, P., Hall, K Sundby, Bertulli, R., Bielack, S.S., Comandone, A., Egerer, G., Hansmeier, A., Palmerini, E., Smeland, S., Ferrari, S.

Get full text

1675PD - EURO-B.O.S.S.: Outcome in rare non-osteosarcoma bone sarcoma by Reichardt, P., Hall, K Sundby, Bertulli, R., Bielack, S.S., Comandone, A., Egerer, G., Hansmeier, A., Palmerini, E., Smeland, S., Ferrari, S.

“…The EUROpean Bone over 40 Sarcoma Study included patients with 41 to 65 years of age with primary malignant bone sarcoma treated with intensive multiagent…”
Get full text

443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082) by Gaspar, N., Campbell-Hewson, Q., Bielack, S.S., Campbell, M., Bautista, F., Meazza, C., Janeway, K., Dela Cruz, F.S., Whittle, S., Morgenstern, D.A., Dutta, L., McKenzie, J., O'Hara, K., Huang, J., Okpara, C.E., Bidadi, B., Koh, K-N., Moreland, B.

Get full text

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion by Bielack, S S, Cox, M C, Nathrath, M, Apel, K, Blattmann, C, Holl, T, Jenewein, R, Klenk, U, Klothaki, P, Müller-Abt, P, Ortega-Lawerenz, S, Reynolds, M, Scheer, M, Simon-Klingenstein, K, Stegmaier, S, Tupper, R, Vokuhl, C, von Kalle, T

“…The ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid,…”
Get full text

1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082) by Gaspar, N., Campbell-Hewson, Q., Bielack, S.S., Campbell, M., Bautista, F., Meazza, C., Janeway, K., Dela Cruz, F.S., Whittle, S.B., Morgenstern, D.A., Dutta, L., McKenzie, J., O'Hara, K., Huang, J., Okpara, C.E., Bidadi, B., Koh, K-N., Morland, B.

Get full text

A special jubilee: 100 fake osteosarcoma articles by Bielack, S.S., Palmerini, E.

Get full text

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach by Lassen, U N, Albert, C M, Kummar, S, van Tilburg, C M, Dubois, S G, Geoerger, B, Mascarenhas, L, Federman, N, Schilder, R J, Doz, F, Berlin, J D, Oh, D-Y, Bielack, S S, McDermott, R, Tan, D S, Cruickshank, S, Ku, N C, Cox, M C, Drilon, A, Hong, D S

Get full text

Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma by Gaspar, N., Sirvent, F J Bautista, Venkatramani, R., Longhi, A., Lervat, C., Casanova, M., Aerts, I., Bielack, S.S., Entz-Werle, N., Strauss, S., He, C., Thebaud, E., Locatelli, F., Morland, B., Melcon, S Gallego, Nieto, A Cañete, Marec- Bérard, P., Gambart, M., Rossig, C., Campbell-Hewson, Q.

Get full text

1676PD - Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma by Gaspar, N., Sirvent, F J Bautista, Venkatramani, R., Longhi, A., Lervat, C., Casanova, M., Aerts, I., Bielack, S.S., Entz-Werle, N., Strauss, S., He, C., Thebaud, E., Locatelli, F., Morland, B., Melcon, S Gallego, Nieto, A Cañete, Marec- Bérard, P., Gambart, M., Rossig, C., Campbell-Hewson, Q.

“…Lenvatinib (LEN) is a multikinase inhibitor of VEGFR1–3 and other targets. We report data from phase Ib dose-finding and phase II expansion cohorts of LEN +…”
Get full text

Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project by Stiller, C.A., Bielack, S.S., Jundt, G., Steliarova-Foucher, E.

“…Data on 5572 children and adolescents diagnosed with malignant bone tumours (International Classification of Childhood Cancer, Group VIII) before the age of 20…”
Get full text

ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas by Wilhelm, M., Dirksen, U., Bielack, S.S., Whelan, J.S., Lewis, I.J., Jürgens, H., Ferrari, S., Sundby Hall, K., Cleton-Jansen, A.M., Stark, D.

“…Teenagers and young adults (TYA) cancer contributes substantially to morbidity and mortality in a population with much to offer society. TYA place distinct…”
Get full text